Výsledky vyhledávání - "Joachim Kiemle-Kallee"

Introduction: SOT101 (previously SO-C101), a fusion protein of IL-15 and the IL-15 receptor α sushi+ domain, was investigated in an open-label, multicenter, dose-escalation study as monotherapy and in combination with pembrolizumab in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1f78b76206d89cd856d8458d873a4d51
https://doi.org/10.1158/1538-7445.am2022-ct040

Zobrazit plný text záznamu

Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors

Autor: Elena Garralda, Aung Naing, Vladimir Galvao, Patricia LoRusso, Peter Grell, Philippe Alexandre Cassier, Carlos A. Gomez-Roca, Iphigenie Korakis, David Bechard, Lenka Palova Jelinkova, Irena Adkins, Sascha Tillmanns, Joachim Kiemle-Kallee, Aurelien Marabelle, Stephane Champiat

Publikováno v: Journal of Clinical Oncology. 40:2502-2502

2502 Background: SOT101 (previously SO-C101) is a fusion protein of IL-15 and the IL-15 receptor α sushi+ domain. Synergistic effects of SOT101 and an anti-programmed cell death protein 1 antibody have been validated in various tumor mouse models in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dde2fcba9d0f2837119dfa217484d482
https://doi.org/10.1200/jco.2022.40.16_suppl.2502

Zobrazit plný text záznamu

Autor: Joachim Kiemle-Kallee, Aurélien Marabelle, Aung Naing, Richard Sachse, Peter Grell, Filip Janku, Vladimir Galvao, David Bechard, Stéphane Champiat, Ellena Garralda, Patricia LoRusso

Publikováno v: Journal for ImmunoTherapy of Cancer. 9:A534-A534

BackgroundSO-C101 is a superagonist fusion protein of IL-15 and the IL-15 receptor α sushi+ domain. SO-C101 was investigated in a multicenter, open-label, dose escalation study as monotherapy and in combination with pembrolizumab in patients with se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2cb60664ee73f69205c712a067738e45
https://doi.org/10.1136/jitc-2021-sitc2021.502

Zobrazit plný text záznamu

484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

Autor: Elena Garralda, Vladimir Galvao, Stephane Champiat, Patricia LoRusso, Peter Grell, Aung Naing, Filip Janku, Richard Sachse, David Bechard, Joachim Kiemle-Kallee, Aurelien Marabelle

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundSO-C101 (IL 15/IL-15Rα sushi + domain fusion protein) was investigated in a multicenter, open-label, dose escalation study as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic tumors (NCT042341

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2b73d0480ee920d45e1b303b6b0ef3
https://doi.org/10.1136/jitc-2021-sitc2021.484

Zobrazit plný text záznamu

Abstract CT149: MP0250, a VEGF- and HGF-blocking multi-DARPin drug candidate, in combination with tyrosine-kinase-inhibitors targeting EGFR-mutated NSCLC: Preclinical rationale and phase Ib/II study outline

Autor: Keith M. Dawson, Frank Hermann, Andreas Harstrick, Michael T. Stumpp, Joachim Kiemle-Kallee, Jutta Haunschild, Ulrike Fiedler, Sandra Dietschy

Publikováno v: Cancer Research. 78:CT149-CT149

Background: Relapse of patients with EGFR-mutated NSCLC treated with TKI regimens is most often due to TK mutation but also in a significant number of cases due to upregulation of bypass pathways, the most common being the HGF/cMET signaling pathway.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f8cd323aa997dfc981304ea494f9146
https://doi.org/10.1158/1538-7445.am2018-ct149

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání